Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

June 02, 2015 10:28 AM ET


Company Overview of VaxInnate, Inc.

Company Overview

VaxInnate, Inc., a biotechnology company, engages in the development and production of vaccines for pandemic and seasonal influenza diseases. Its products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company's products are used in the treatment of various diseases, including bacterial, viral, and parasitic infections. VaxInnate, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

3 Cedar Brook Drive

Suite 1

Cranbury, NJ 08512

United States

Founded in 2002





Key Executives for VaxInnate, Inc.

Chief Executive Officer, President and Director
Age: 59
Scientific Founder
Scientific Founder
Chief Financial Officer
Age: 53
Vice President of Business Development
Age: 55
Compensation as of Fiscal Year 2014.

VaxInnate, Inc. Key Developments

VaxInnate, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:00 AM

VaxInnate, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Wayne F. Pisano, Chief Executive Officer, President and Director.

VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly

VaxInnate Corporation announced the initiation of a double-blind, randomized, placebo-controlled Phase 1b/2 study of VAX2012Q in healthy adults 65-75 years of age. VAX2012Q is the company's seasonal quadrivalent influenza vaccine candidate, which incorporates a bacterial flagellin protein designed to enhance the adaptive immune response to the vaccine. This Phase 1b/2 study will evaluate the vaccine's safety and immunogenicity in this elderly population. The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, has funded the production of VAX2012Q for use in this clinical study under contract No. HHSO100201100011C. VAX2012Q is comprised of four seasonal influenza strains, each fused to a flagellin protein, which acts as a toll-like receptor (TLR) ligand. The TLR class of proteins is known to activate the innate immune system, which in turn enhances the adaptive immune response to vaccines. In a previous clinical study, VAX125, a vaccine comprised of one seasonal influenza H1N1 strain, was shown to elicit a robust immune response in the elderly. This Phase 1b/2 study will enroll up to 200 healthy adults 65-75 years of age, who will be administered either VAX2012Q or placebo. In addition to safety, which is the trial's primary objective, the study will also assess the dose levels necessary to produce a robust immune response in the majority of study participants. Individuals will be monitored for one year following their vaccination to assess long-term safety.

VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly

VaxInnate Corporation provided an update on clinical development plans for the Company’s experimental recombinant quadrivalent vaccine, VAX2012Q. VaxInnate plans to advance VAX2012Q into a Phase 1b/2 study for the prevention of seasonal influenza in elderly individuals by the end of 2014. Up to 200 healthy adults age 65-75 years will be enrolled in this multi-center, randomized, double-blind, placebo-controlled, dose-escalating Phase 1b/2 study. VAX2012Q was also assessed in a Phase 1 study in adults 18-40 years of age initiated in March 2014. This Phase 1 study was the subject of an abstract accepted at the recent Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and showed that doses up to 18 mcg were generally well tolerated and immunogenic with mild to moderate arm pain as the most common adverse event reported.

Similar Private Companies By Industry

Company Name Region
EcoChoice Protein Corporation United States
Gene Solutions LLC United States
Calimmune, Inc. United States
Bionova Holding Corporation United States
Evolutionary Genomics, Inc. and EG I, LLC United States

Recent Private Companies Transactions

Private Placement
September 25, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VaxInnate, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at